Infinity BiologiX, which previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020, said Sept. 15 it acquired U.K.-based biospecimen storage specialists Roylance Pharma.
“We are excited to welcome the Roylance Pharma team into the IBX family. Combining our two great organizations serves to strengthen the support we provide our clients whilst accelerating our already impressive growth on an international scale,” said Infinity BiologiX Chief Executive Officer Robin Grimwood.
Terms of the deal were not disclosed.
“Joining Roylance Pharma and IBX is a natural fit that will benefit both groups of clients and teams,” said Benedict Roylance, co-founder of Roylance Pharma. “Expanding our reach internationally and sharing the wealth of expertise within both businesses means we can drive further growth and offer greater support in our clients’ research projects.”
“Many research and development projects operate internationally and through this rapid expansion, IBX is well placed to provide quality assurance and control with consistent SOPs across regions. As we have just celebrated our first year as IBX (previously RUCDR) I am enormously proud to lay another important piece of our foundation. We look forward to leveraging this footprint expansion as we continue to prove IBXs commitment to our clients’ success,” said Grimwood.
